home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550872.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
2KB
|
29 lines
Document 0872
DOCN M9550872
TI The need for additional options in the treatment of human
immunodeficiency virus infection.
DT 9505
AU Volberding P; San Francisco General Hospital, AIDS Program, University
of; California 94110.
SO J Infect Dis. 1995 Mar;171 Suppl 2:S150-4. Unique Identifier : AIDSLINE
MED/95164991
AB Current therapy for human immunodeficiency virus (HIV) infection is
inadequate to control the progression of the disease. Although existing
nucleoside analogues, such as zidovudine, have clear benefits, they also
have drawbacks, including toxicity and the possibility of drug
resistance. In addition, the timing of therapy and the use of
monotherapy versus combination therapy as initial treatment have not
been definitively established. HIV drugs currently in development
include newer nucleoside analogues, such as stavudine and lamivudine,
nonnucleoside reverse transcriptase inhibitors, and protease inhibitors.
The addition of these agents to the antiretroviral armamentarium will
expand the treatment options available to clinicians who treat patients
with HIV infection.
DE Antiviral Agents/*THERAPEUTIC USE Dideoxynucleosides/THERAPEUTIC USE
Human HIV Infections/*DRUG THERAPY JOURNAL ARTICLE REVIEW REVIEW,
TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).